FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101568174> ?p ?o ?g. }

• W2101568174 endingPage "9156" @default.
• W2101568174 startingPage "9153" @default.
• W2101568174 abstract "The ability to engage cationic substrates such as iminium and oxocarbenium ions in transition-metal-catalyzed C–C bond formation is a challenging task that has recently seen successful application.[1] In this context, we reported that a low-valent Ni catalyst facilitates unprecedented Suzuki–Miyaura cross-coupling reactions with allylic N,O- and O,O-acetal substrates.[2,3] Mechanistic studies revealed that boronic acids mediate allylic C–O activation, with oxidative addition occurring between the resulting iminium or oxocarbenium ion intermediate and the Ni catalyst (Scheme 1a).[4] The demonstration that a transition-metal catalyst can oxidatively insert into these prochiral intermediates offers a number of exciting possibilities for reaction design and enantioselective synthesis. Herein, we demonstrate that this activation mode enables the enantioselective synthesis of α-substituted 2,3-dihydro-4-pyridones by Negishi cross-coupling with N-acyl pyridinium ions (Scheme 1b).Scheme 1Nickel-catalyzed cross-coupling with iminium ions.α-Substituted piperidines are among the most prevalent scaffolds in biologically active small molecules, and also serve as building blocks for natural product and pharmaceutical synthesis.[5] The stereoselective addition of carbon-centered nucleophiles to activated pyridines is a particularly attractive route to these core structures.[6] Seminal work from the groups of Comins and Charette established the possibility of using stoichiometric chiral acylating agents to control the stereo-chemical outcome of C–C bond formation.[7,8] However, only two examples have been described for the catalytic enantio-selective addition of organometallic reagents to prochiral N-acyl/alkyl pyridinium ions.[9] Both of these reactions likely proceed through the addition of a chiral [M]-R species into a prochiral pyridinium salt (M =Cu or Rh). As such, the strategy is limited to reactions with either highly nucleophilic R groups or highly electrophilic pyridinium ions. As the oxidative addition/reductive elimination mechanism that we elucidated for cross-coupling with N-acyl quinolinium salts should not be subject to these same limitations, we envisioned that its application to enantioselective cross-coupling with pyridinium ions could provide a complementary approach to these methods. Furthermore, successful development of such a reaction would demonstrate for the first time that iminium ion activation by Ni0 is subject to highly enantioselective C–C bond formation.One challenge apparent at the outset of our endeavors was potential catalyst poisoning in the presence of free pyridine. To address this issue, we chose to use 4-methoxy-pyridine as a substrate, because it shows substantial formation of a pyridinium salt with chloroformates at −78°C.[10] To enable facile transmetalation at low temperature, a Negishi reaction platform was selected.[11] Notably, when we initiated the reaction at −78°C with warming to RT, the combination of [{(methallyl)NiCl}2] (7.5 mol%) and (R)-Monophos (L1; 18 mol%) was found to promote arylation of 4-methoxypyridine in the presence of phenyl chloroformate and 4-FC6H4ZnBr with low but measurable ee (Table 1, entry 1).[12] Commercial phosphoramidite ligands L2–L4, which bear substituents at the 3 and 3′ positions of the binaphthyl backbone, induced more promising levels of asymmetric induction (up to 91% ee, entries 2–4).[13] Accordingly, an extensive library of 3,3′-substituted ligands was prepared and evaluated, revealing that ligand L7 was optimal (entry 7). With this ligand, the 2,3-dihydro-4-pyridone product 2a was obtained in 95% ee, albeit with moderate reaction efficiency.Table 1Ligand optimization.[a]Upon selection of an optimal ligand (L7), we pursued further optimization of the reaction parameters. Among the Ni sources examined, NiBr2·diglyme was most promising, as its use increased the yield of the reaction while maintaining high levels of enantioselectivity (Table 2, entry 2). This result is particularly attractive because NiBr2·diglyme is air stable, thus permitting the reactions to be set up on the benchtop. In the absence of a Ni source, the reaction performs poorly, demonstrating that Ni induces substantial rate acceleration (entry 5). Additional changes to the reaction conditions, such as decreasing the amount of nucleophile or changing the identity of the acylating agent, had a negative effect on reactivity (entries 6–8). On the other hand, decreasing the Ni loading from 15 mol% to 10 mol% provided nearly identical levels of enantioselectivity and reaction efficiency (entry 9). A gram-scale reaction set up on the benchtop using a catalyst loading of 5 mol% delivered 2a in 73% yield and 93% ee (entry 10).Table 2Optimization of reaction conditions.[a]Having identified conditions to prepare 2a in high yield and enantiomeric excess, a survey of aryl zinc nucleophiles was conducted to evaluate the scope of the reaction (Scheme 2).[14] Phenyl zinc bromide afforded 2,3-dihydro-4-pyridone 2b in 92% ee, which could be recrystallized to >99% ee in 78% yield. Generally, ortho-, meta-, and para-substituted zinc nucleophiles are well tolerated. Reactions with electron-withdrawing zinc reagents fared exceptionally well, delivering products bearing 3,5-difluoro (2c), 4-Cl (2d), 4-CF3 (2e), 4-cyano (2 f), and 4-sulfonamide (2g) groups in 96–99% ee. Notably, zinc reagents substituted with methyl ester and pivaloate groups afforded products (2j, 2k) that are otherwise inaccessible by standard Grignard methods. Moreover, a reaction with a heteroaromatic nucleophile furnished 2l in excellent ee and yield, highlighting the potential of this strategy to deliver medicinally relevant products. Whereas electron-neutral aryl zinc nucleophiles such as 4-vinyl (2m), 4-Me (2n) and 2-naphthyl (2o) performed modestly in terms of enantioselectivity, electron-rich nucleophiles such as 4-OMe (2p) underwent reaction with no stereoinduction owing to a competitive racemic background reaction (77% yield of isolated product without nickel).[15] An additional limitation is that other electrophile partners, including pyridine, 2-methoxy-pyridine, and 4-dimethylaminopyridine (DMAP), are not competent under the optimized conditions.Scheme 2Scope of aryl zinc nucleophiles in the reaction. Yields and ee values are the average of two runs on a 0.5 mmol scale. [a] Yield and ee after recrystallization from ether. [b] Reaction warmed to RT. [c] Reaction warmed to −20°C. [d] Derived ...To understand the mechanism of this transformation, we studied the stoichiometric reaction of Ni0 with the pyridinium salt derived from 4-methoxypyridine and phenyl chloroformate, which was generated in situ. For simplicity, we chose to conduct our studies with PPh3, as it is a competent ligand for the reaction of interest, providing (±)-2a in 87% yield under otherwise standard reaction conditions.[13] In the event, an air-sensitive allyl–NiII adduct 3 was produced in 87% yield (Scheme 3), the structure of which was confirmed by single crystal X-ray diffraction (Figure 1). When subjected to 4-FC6H4ZnBr, allyl adduct 3 underwent C–C bond formation, providing 2a in 25% yield [Eq. (1)]. Furthermore, 3 is catalytically competent, providing racemic 2a in 68% yield at 10 mol% catalyst loading [Eq. (2)]. Taken together, these data provide compelling evidence for a redox mechanism distinct from that typically considered for transition-metal-catalyzed addition reactions to pyridinium ions.Figure 1Solid-state structure of allyl NiII complex 3. Ellipsoids set at 30% probability. Hydrogen atoms omitted for clarity.Scheme 3Stoichiometric reaction between Ni0 and a pyridinium ion.(1)(2)With these data in mind, we propose the reaction mechanism shown in Scheme 4. Oxidative addition of Ni0 into the C–N π bond of the pyridinium salt provides a NiII allyl intermediate analogous to complex 3.[16] Subsequent transmetalation with ArZnBr gives diorganonickel intermediate 4, which can undergo reductive elimination to regenerate the Ni0 catalyst and complete the catalytic cycle.[17] The presence of the methoxy substituent at C4 presumably serves as a blocking group, favoring the observed regioisomeric dihydropyridine 5.[18] Acid hydrolysis of 5 then affords the 2,3-dihydro-4-pyridone product 2.Scheme 4Proposed catalytic cycle.In conclusion, we have described a novel nickel-catalyzed enantioselective Negishi cross-coupling reaction of 4-methoxypyridinium salts. A broad range of synthetically valuable enantioenriched 2,3-dihydro-4-pyridones can be obtained from commercially available or readily prepared starting materials and an air-stable, inexpensive NiII precatalyst. Preliminary mechanistic data support the intermediacy of a NiII π-allyl intermediate generated upon ionic oxidative addition of Ni0 to the pyridinium electrophile. The study provides an exciting indication of the generality of this mode of activation and its amenability to asymmetric catalysis." @default.
• W2101568174 created "2016-06-24" @default.
• W2101568174 creator A5039323621 @default.
• W2101568174 creator A5056073819 @default.
• W2101568174 creator A5074434542 @default.
• W2101568174 creator A5077633918 @default.
• W2101568174 date "2013-07-10" @default.
• W2101568174 modified "2023-10-17" @default.
• W2101568174 title "Nickel-Catalyzed Enantioselective Arylation of Pyridinium Ions: Harnessing an Iminium Ion Activation Mode" @default.
• W2101568174 cites W1520596554 @default.
• W2101568174 cites W1969061662 @default.
• W2101568174 cites W1969810452 @default.
• W2101568174 cites W1971197395 @default.
• W2101568174 cites W1971588022 @default.
• W2101568174 cites W1984470661 @default.
• W2101568174 cites W1995370492 @default.
• W2101568174 cites W1996892864 @default.
• W2101568174 cites W1996945954 @default.
• W2101568174 cites W1998347571 @default.
• W2101568174 cites W2004355958 @default.
• W2101568174 cites W2029116557 @default.
• W2101568174 cites W2051039671 @default.
• W2101568174 cites W2052475955 @default.
• W2101568174 cites W2055613164 @default.
• W2101568174 cites W2058073539 @default.
• W2101568174 cites W2063700634 @default.
• W2101568174 cites W2076543428 @default.
• W2101568174 cites W2076556331 @default.
• W2101568174 cites W2080270252 @default.
• W2101568174 cites W2089953302 @default.
• W2101568174 cites W2098150681 @default.
• W2101568174 cites W2101833237 @default.
• W2101568174 cites W2115311209 @default.
• W2101568174 cites W2123188613 @default.
• W2101568174 cites W2147141808 @default.
• W2101568174 cites W2164877111 @default.
• W2101568174 cites W2317032969 @default.
• W2101568174 cites W2322296010 @default.
• W2101568174 cites W2326610454 @default.
• W2101568174 cites W2949435053 @default.
• W2101568174 cites W2949535454 @default.
• W2101568174 cites W2949728932 @default.
• W2101568174 cites W2950746180 @default.
• W2101568174 cites W2952074443 @default.
• W2101568174 cites W4231140095 @default.
• W2101568174 cites W4238565372 @default.
• W2101568174 cites W4249188159 @default.
• W2101568174 doi "https://doi.org/10.1002/anie.201303994" @default.
• W2101568174 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4811189" @default.
• W2101568174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23843307" @default.
• W2101568174 hasPublicationYear "2013" @default.
• W2101568174 type Work @default.
• W2101568174 sameAs 2101568174 @default.
• W2101568174 citedByCount "71" @default.
• W2101568174 countsByYear W21015681742013 @default.
• W2101568174 countsByYear W21015681742014 @default.
• W2101568174 countsByYear W21015681742015 @default.
• W2101568174 countsByYear W21015681742016 @default.
• W2101568174 countsByYear W21015681742017 @default.
• W2101568174 countsByYear W21015681742018 @default.
• W2101568174 countsByYear W21015681742019 @default.
• W2101568174 countsByYear W21015681742020 @default.
• W2101568174 countsByYear W21015681742021 @default.
• W2101568174 countsByYear W21015681742022 @default.
• W2101568174 countsByYear W21015681742023 @default.
• W2101568174 crossrefType "journal-article" @default.
• W2101568174 hasAuthorship W2101568174A5039323621 @default.
• W2101568174 hasAuthorship W2101568174A5056073819 @default.
• W2101568174 hasAuthorship W2101568174A5074434542 @default.
• W2101568174 hasAuthorship W2101568174A5077633918 @default.
• W2101568174 hasBestOaLocation W21015681742 @default.
• W2101568174 hasConcept C145148216 @default.
• W2101568174 hasConcept C146686406 @default.
• W2101568174 hasConcept C161790260 @default.
• W2101568174 hasConcept C178790620 @default.
• W2101568174 hasConcept C185592680 @default.
• W2101568174 hasConcept C21951064 @default.
• W2101568174 hasConcept C2777221202 @default.
• W2101568174 hasConcept C2778567177 @default.
• W2101568174 hasConcept C504270822 @default.
• W2101568174 hasConceptScore W2101568174C145148216 @default.
• W2101568174 hasConceptScore W2101568174C146686406 @default.
• W2101568174 hasConceptScore W2101568174C161790260 @default.
• W2101568174 hasConceptScore W2101568174C178790620 @default.
• W2101568174 hasConceptScore W2101568174C185592680 @default.
• W2101568174 hasConceptScore W2101568174C21951064 @default.
• W2101568174 hasConceptScore W2101568174C2777221202 @default.
• W2101568174 hasConceptScore W2101568174C2778567177 @default.
• W2101568174 hasConceptScore W2101568174C504270822 @default.
• W2101568174 hasIssue "35" @default.
• W2101568174 hasLocation W21015681741 @default.
• W2101568174 hasLocation W21015681742 @default.
• W2101568174 hasLocation W21015681743 @default.
• W2101568174 hasLocation W21015681744 @default.
• W2101568174 hasOpenAccess W2101568174 @default.
• W2101568174 hasPrimaryLocation W21015681741 @default.
• W2101568174 hasRelatedWork W2001911836 @default.
• W2101568174 hasRelatedWork W2132269688 @default.

• next